Our Pricing

Compare Wegovy Prices When Switching From Other Treatments

Published on: June 03, 2026

When you compare Wegovy prices UK switching options, understanding the clinical differences and cost implications helps you make an informed decision. At Cured Pharmacy, Wegovy starts from £79.00 with transparent upfront pricing, making it easier to evaluate whether switching from your current weight loss treatment is right for you.

Why Patients Compare Wegovy Prices When Switching Treatments

Many UK patients initially start with daily injectable treatments like Saxenda or oral medications like Orlistat, then explore switching to once-weekly Wegovy for greater convenience and efficacy. Clinical trial data shows semaglutide (Wegovy's active ingredient) delivered an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial, compared to 2.4% with placebo [1].

Cost is a significant factor when comparing treatment options. While pricing varies across UK pharmacies, transparent upfront costs allow you to budget effectively and avoid unexpected consultation fees or hidden charges. At Cured Pharmacy, all prices are displayed before your free clinical assessment, ensuring you know exactly what you'll pay subject to prescriber approval.

Switching between weight loss medications requires clinical oversight. A UK-registered prescriber will assess your current treatment response, medical history, and any side effects you've experienced to determine whether Wegovy is clinically appropriate for your circumstances.

Wegovy vs Saxenda: Key Differences for Switchers

Saxenda contains liraglutide, a once-daily GLP-1 receptor agonist, whilst Wegovy contains semaglutide, a once-weekly formulation. Both work by mimicking the GLP-1 hormone to reduce appetite and slow gastric emptying, but their dosing schedules and clinical outcomes differ significantly [2].

In head-to-head comparisons, semaglutide demonstrated superior weight loss outcomes. The STEP 8 trial showed patients on semaglutide 2.4mg weekly achieved 15.8% average body weight reduction compared to 6.4% with liraglutide 3.0mg daily over 68 weeks [2]. This represents more than double the weight loss with fewer injections.

Patients switching from Saxenda to Wegovy typically cite injection frequency as a primary motivator. Once-weekly dosing improves treatment adherence and reduces the burden of daily injections, which can be particularly beneficial for those with busy schedules or needle anxiety.

Switching Protocol: What to Expect

When switching from Saxenda to Wegovy, your prescriber will typically stop liraglutide and start you on Wegovy's lowest dose (0.25mg weekly) to minimise gastrointestinal side effects. The dose escalates gradually over 16-20 weeks until you reach the maintenance dose of 2.4mg weekly, subject to tolerability and clinical response.

Wegovy vs Mounjaro: Comparing Semaglutide and Tirzepatide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK. Whilst Wegovy activates only the GLP-1 pathway, Mounjaro targets both GLP-1 and GIP receptors, potentially producing greater weight loss in clinical trials [3].

The SURPASS-2 trial directly compared tirzepatide with semaglutide 1.0mg in adults with type 2 diabetes. Participants on the highest tirzepatide dose (15mg) achieved significantly greater HbA1c reduction and weight loss than those on semaglutide [3]. However, higher doses may also increase gastrointestinal side effects.

When you compare Wegovy prices UK switching considerations, tirzepatide typically commands higher pricing due to its dual-action mechanism and newer market entry. Patients switching from Mounjaro to Wegovy often do so for cost reasons or if they experienced tolerability issues with tirzepatide's higher doses.

Which Treatment Offers Better Value?

Value depends on individual response, tolerability, and budget. Wegovy's established efficacy profile and competitive pricing make it an accessible option for many UK patients. Your prescriber will help determine which medication aligns with your clinical needs and financial considerations.

Switching From Orlistat or Mysimba to Wegovy

Orlistat works through a completely different mechanism than GLP-1 receptor agonists. It blocks fat absorption in the digestive system, leading to modest weight loss of approximately 3kg more than diet and exercise alone over 12 months [4]. Many patients find the gastrointestinal side effects (oily stools, increased bowel movements) challenging to manage long-term.

Mysimba combines naltrexone and bupropion to reduce appetite through central nervous system pathways. Whilst it offers an oral alternative to injections, clinical trials showed average weight loss of 5-10% over one year, typically lower than outcomes seen with GLP-1 receptor agonists [4].

Patients switching from oral medications to Wegovy often report improved weight loss outcomes and better long-term adherence despite the transition to injections. The once-weekly dosing schedule and pre-filled pen design make Wegovy more convenient than daily tablets for many individuals.

Understanding Wegovy Pricing Structure in the UK

Wegovy pricing in UK pharmacies varies based on dose strength and supply duration. At Cured Pharmacy, transparent pricing starts from £79.00, with the exact cost determined by your prescribed dose following clinical assessment. All prices include the medication, UK prescriber consultation, and discreet home delivery.

When comparing Wegovy prices UK switching scenarios, consider the total monthly cost rather than single-pen pricing. The maintenance dose of 2.4mg requires four pens per 28-day supply, so understanding the full treatment cost helps you budget accurately. Cured Pharmacy displays all dose-specific pricing before you begin your consultation.

Some UK pharmacies charge separate consultation fees, membership subscriptions, or delivery charges that significantly increase the total cost. At Cured Pharmacy, the price you see includes everything—no hidden fees, no mandatory subscriptions, and no surprise charges at checkout.

Lowest Price Guarantee

Cured Pharmacy guarantees the lowest Wegovy prices in the UK. If you find a lower price at another UK-registered pharmacy for the same dose and supply, we'll match it. This commitment ensures you receive genuine UK-licensed medication at the most competitive rate available.

How to Switch to Wegovy: Clinical Assessment Process

Switching to Wegovy requires a clinical assessment by a UK-registered prescriber, even if you're currently taking another weight loss medication. The online consultation at Cured Pharmacy takes under 3 minutes and covers your medical history, current medications, previous treatment response, and weight loss goals.

Your prescriber will evaluate whether Wegovy is clinically appropriate based on your BMI, existing health conditions, and any contraindications. MHRA licensing criteria require a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea.

If approved, your prescription is sent directly to Cured Pharmacy's dispensary where superintendent pharmacist Tarun Kumar (GPhC 2233073) and his team prepare your medication for discreet next-day delivery. All Wegovy pens are genuine UK-licensed products stored and handled according to strict GPhC standards.

Patients switching from other treatments should inform their prescriber about any side effects experienced previously. This information helps determine the appropriate starting dose and escalation schedule to minimise adverse effects whilst optimising weight loss outcomes.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D. M., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
3. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2014). Weight management: lifestyle services for overweight or obese adults (PH53). NICE. https://www.nice.org.uk/guidance/ph53 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between weight loss treatments.